Effects of Korean Red Ginseng Intake on Uterine Fibroid Size and Hormonal Profiles

The organized laboratory, clinical and epidemiological studies : Effects of Korean red ginseng on reproductive aged women with uterine leiomyoma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0011687

Enrollment

Registered

2026-03-06

Start date

2015-12-31

Completion date

Unknown

Last updated

2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Test Group (KRG): Korean Red Ginseng 3g/day (Oral, 6 months) Control Group (Placebo): Red Ginseng-matched placebo (Oral, 6 months)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: - Women aged 20–45 years with uterine fibroids measuring 1–8 cm in diameter on ultrasonography - To minimize measurement variability, patients with a single uterine fibroid were preferentially included; in cases of multiple fibroids, patients were eligible only if, aside from the largest fibroid, there were no more than three additional fibroids measuring =1 cm - Patients able to undergo follow-up ultrasonographic evaluation of uterine fibroids at 0, 3, and 6 months using transvaginal or transrectal ultrasound

Exclusion criteria

Exclusion criteria: - Patients with uterine fibroids requiring immediate medical or surgical intervention due to abnormal uterine bleeding or heavy menstrual bleeding - Patients with anemia requiring active medical or surgical management - Patients diagnosed with menopause regardless of age, or women aged =45 years classified as perimenopausal even with regular menstrual cycles - Patients who have undergone myomectomy, uterine artery embolization, levonorgestrel-releasing intrauterine system insertion, medical therapy affecting fibroids, or other fibroid-related treatments within the past year - Cases in which malignant transformation is suspected based on imaging findings or clinical presentation of the mass - Patients currently receiving hormone therapy

Design outcomes

Primary

Measure	Time frame
Change in maximal diameter of the index leiomyoma	—

Secondary

Measure	Time frame
Leiomyoma anatomical type per FIGO subclassification;Complete blood count ;Serum ferritin;Aspartate Aminotransferase ;Alanine Aminotransferase;Gamma-Glutamyl Transferase;Follicle-Stimulating Hormone;Luteinizing Hormone;Estradiol;Testosterone;Sex Hormone-Binding Globulin	—

Countries

Korea, Republic of

Contacts

Public ContactYunjeong Park

Yonsei University Health System, Severance Hospital

mavrik8@naver.com+82-2-2228-2247

Outcome results